FGFR1 and central nervous system cancer: Alternatively, IDH1/2 wildtype ALGGs that lack a genomic GBM signature should be evaluated for other potential oncogenic drivers, including mutations such as FGFR1 p.K656E, which has been identified in pediatric gliomas.